Table 5.
Patient characteristics in [177Lu]Lu-DOTA-TATE (ERASMUS) before and after matching to NCT00428597.a
| Patient characteristic | ERASMUS (pre-match) |
ERASMUS (post-match Sunitinib) |
NCT00428597 |
ERASMUS (post-match BSC) |
NCT00428597 |
|
|---|---|---|---|---|---|---|
| [177Lu]Lu-DOTA-TATE | [177Lu]Lu-DOTA-TATE | Sunitinib | [177Lu]Lu-DOTA-TATE | BSC | ||
| N | N | 62 | 62 | 86 | 62 | 85 |
| Effective sample size: | 48 | 35 | ||||
| Age | Mean (median) | 58 | 56 | NA (56) | 57 | NA (57) |
| ECOG performance status | 0 | 23% | 62% | 62% | 48% | 48% |
| 1 | 77% | 38% | 38% | 52% | 52% | |
| Previous radiotherapy | Yes | 3% | 9% | 10% | 14% | 14% |
| No | 97% | 91% | 90% | 86% | 86% | |
| Previous chemotherapy | Yes | 13% | 9% | 8% | 16% | 16% |
| No | 87% | 91% | 92% | 84% | 84% | |
| Sex | Male | 45% | 58% | 49% | 53% | 47% |
| Female | 55% | 42% | 51% | 47% | 53% | |
| Previous surgery | Yes | 45% | 40% | 88% | 40% | 91% |
| No | 55% | 60% | 12% | 60% | 9% | |
| Non-functional | Yes | 48% | 40% | 49% | 44% | 52% |
| No | 52% | 60% | 51% | 56% | 48% | |
| Median time from initial diagnosis | Years | 1.24 | 1.24 | 2.4 | 1.24 | 2.4 |
| Weights | Mean | 1.00 | 1.00 | |||
| Range | (0.00–5.32) | (0.13–6.95) |
BSC, best supportive care; ECOG, Eastern Cooperative Oncology Group; NA, not available.
a
A histogram describing the full distribution of weights is provided in the data supplement.